HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma

Midulla, C; Manganaro, Lucia; Longo, Flavia; Viggiani, Valentina; Frati, Luigi; Granato, Teresa; Anastasi, Emanuela

doi:10.1007/s13277-012-0376-5

Cited by 18 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the reported detection rate for stage I and II is comparable with that reported for MRI. 10,22 In our study, we found a strong correlation between HE4 and 2 other relevant prognostic factors of early stage EC: MI and tumor dimension. The pathological diagnosis of these 2 EC features is related to the risk of nodal metastases and the need of adjuvant therapy, 23 thus, the preoperative knowledge could be helpful in the correct operative planning including the pelvic and aortic lymphadenectomy.…”

Section: Discussionsupporting

confidence: 60%

Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study

Fanfani

Restaino

Cicogna

et al. 2017

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 60%

Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study

Fanfani

Restaino

Cicogna

et al. 2017

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…The application of HE4 for the prognosis and prediction of relapse for ovarian cancer patients has also been investigated. Midulla et al reported that the elevated serum HE4 level before therapy significantly correlated with high tumor grade, serous histology, peritoneal involvement, nodal invasion, tumor stage, operative time, and residual tumor size [13]. The elevated concentration of serum HE4 level was demonstrated to be an independent indicator for the worse progression-free survival (PFS) and overall survival, while serum CA125 and HER2 was not [14].…”

Section: Introductionmentioning

confidence: 99%

“…Nassir et al reported that HE4 in combination with CA125 performed better than CA125 and HE4 alone in predicting relapse within 12 months after first-line chemotherapy [17]. Overall, HE4 has been demonstrated to be a more efficient marker for ovarian cancer than CA125, and it can be used either alone or as a part of ROMA in the differential diagnosis of pelvic masses and prediction of relapse for ovarian cancer patients after treatment [10,[12][13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies

Duan

et al. 2016

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

“…These data indicate that HE4 is superior to CA-125 for estimating the extent of peritoneal carcinomatosis and that it correlates with tumor burden in all surgically treated patients (30)(31)(32).…”

Section: Discussionmentioning

confidence: 74%

Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer

et al. 2013

Self Cite

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate human epididymis protein 4 (HE4) as a marker of epithelial ovarian cancer (EOC) relapse and the combination of this biomarker with contrast-enhanced high-resolution multidetector row computed tomography CE CT imaging to impove the monitoring of EOC patients. Twenty-one patients with advanced EOC (FIGO III/IV) who underwent surgery and adjuvant chemotherapy were retrospectively selected. Each patient contributed 3 serum samples drawn at 3-month intervals: time interval I (1-3 months from surgery), time interval II (4-6 months from surgery) and time interval III (7-10 months from surgery). Serum HE4 and cancer antigen-125 (CA-125) levels were determined by EIA and IRMA assays, respectively. Nine out of the 21 (Group A) women had disease relapse while 12 out of the 21 (Group B) women had stable disease during the follow-up study. Twenty out of the 21 patients underwent at least two CE CT follow-ups with an interval time of ~6 months. One patient did not undergo a second CE CT. In patients with relapsed EOC, an increase in HE4 was noted in 22, 78 and 89% of patients within the time intervals I, II and III, respectively. Positivity for CA-125 was found later at time interval III and only in 44% of patients. Conversely, for EOC patients in remission, increase over the threshold level was observed only for marker CA-125 (4/12). The evaluation of imaging findings at interval time II showed a significant correlation with high levels of HE4 in 6 out of 9 patients with recurrent disease. This study supports the hypothesis that HE4 may serve as an early biomarker for recurrence of EOC.Moreover, HE4 serum levels combined with CE CT imaging may improve the monitoring management of women affected by ovarian cancer.

show abstract

HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma

Cited by 18 publications

References 28 publications

Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study

Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study

Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies

Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer

Contact Info

Product

Resources

About